Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05905497 · ClinicalTrials.gov registry record · Phase 1
The Study of Bemnifosbuvir in Healthy Japanese Subjects
A Phase 1 study, sponsored by Atea Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05905497 is a Phase 1 study that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT05905497, a Phase 1 study, has completed, sponsored by Atea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability and pharmacokinetics (PK) of Bemnifosbuvir in healthy adult Japanese subjects
Interventions
- DRUG Bemnifosbuvir (BEM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-04-26 |
| Est. Completion | 2023-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05905497
The ClinicalTrials.gov registry entry for NCT05905497 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atea Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bemnifosbuvir (BEM) is the first listed.
NCT05905497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05905497 about?
NCT05905497 is a clinical study titled "The Study of Bemnifosbuvir in Healthy Japanese Subjects". This study will assess the safety, tolerability and pharmacokinetics (PK) of Bemnifosbuvir in healthy adult Japanese subjects
What is the current status of trial NCT05905497?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2023-04-26. Estimated completion is 2023-05-19.
What interventions are being tested in trial NCT05905497?
The interventions under investigation include: Bemnifosbuvir (BEM) (DRUG).
Who is sponsoring clinical trial NCT05905497?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.